Article info

Original research
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Authors

  1. Correspondence to Mark Awad; mark_awad{at}dfci.harvard.edu
View Full Text

Citation

Ricciuti B, Jones G, Severgnini M, et al
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Publication history

  • Accepted March 2, 2021
  • First published March 25, 2021.
Online issue publication 
March 25, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.